Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679445 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
A Phase 2 study of Wet Age-related Macular Degeneration, sponsored by NeoVista.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT00679445: Completed Phase 2 study of Wet Age-related Macular Degeneration, sponsored by NeoVista.
NCT00679445 is a Phase 2 study of Wet Age-related Macular Degeneration that has completed, run by NeoVista. The registered enrollment target is 20 participants, below the 422-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00679445, a Phase 2 study of Wet Age-related Macular Degeneration, has completed, sponsored by NeoVista.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.
Conditions Studied
Interventions
- DEVICE NeoVista Ophthalmic System
Study Locations (2)
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Texas
- Medical Center Ophthalmology Associates - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00679445 record still lists
NCT00679445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 422-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which NeoVista Ophthalmic System is the first listed.
NCT00679445 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00679445 about?
NCT00679445 is a clinical study titled "A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy". The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration that have failed Primary Anti-VEGF therapy.
What is the current status of trial NCT00679445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-12. Estimated completion is 2011-06.
What conditions does trial NCT00679445 study?
This clinical trial studies the following conditions: Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT00679445?
The interventions under investigation include: NeoVista Ophthalmic System (DEVICE).
Who is sponsoring clinical trial NCT00679445?
This trial is sponsored by NeoVista, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679445 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wet Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00679445's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Wet Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wet Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ACTIVE NOT RECRUITING
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia